Erratum: Development of p21 Activated Kinase-Targeted Multikinase Inhibitors That Inhibit Thyroid Cancer Cell Migration (Journal of Clinical Endocrinology and Metabolism (2013) 98:8 (E1314-E1322) (DOI:10.1210/jc.2012-3937));Development of p21 activated kinase-targeted multikinase inhibitors that inhibit thyroid cancer cell migration

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 8, 2013, Pages 1314-

  Ma, Yihui ^a,c   McCarty, Samantha K ^b   Kapuriya, Naval P ^a,d   Brendel, Victoria J ^b   Wang, Chaojie ^b   Zhang, Xiaoli ^b   Jarjoura, David ^b   Saji, Motoyasu ^b   Chen, Ching Shih ^a   Ringel, Matthew D ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c INSTITUTE OF PLANT PROTECTION   (China)

^d Shree M and N Virani Science College   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; 2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE DERIVATIVE; ADENOSINE TRIPHOSPHATE; ANTIMETASTATIC AGENT; MOLECULAR SCAFFOLD; P21 ACTIVATED KINASE; P21 ACTIVATED KINASE 1; P21 ACTIVATED KINASE TARGETED MULTIKINASE INHIBITOR; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIMIGRATION ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL VIABILITY; COMBINATORIAL CHEMISTRY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG SPECIFICITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; THYROID CANCER; TUMOR INVASION;

EID: 84881522542     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2016-1043     Document Type: Erratum

References (29)

1. Manser E, Leung T, Salihuddin H, Zhao ZS, Lim L. A brain serine/ threonine protein kinase activated by Cdc42 and Rac1. Nature. 1994;367:40-46.
2. Bokoch GM. Biology of the p21-activated kinases. Annu Rev Biochem. 2003;72:743-781.
3. Jaffer ZM, Chernoff J. p21-activated kinases: three more join the Pak. Int J Biochem Cell Biol. 2002;34:713-717.
4. Dummler B, Ohshiro K, Kumar R, Field J. Pak protein kinases and their role in cancer. Cancer Metastasis Rev. 2009;28:51-63.
5. Ong CC, Jubb AM, Zhou W, et al. p21-activated kinase 1: PAK'ed with potential. Oncotarget. 2011;2:491-496.
6. Vadlamudi RK, Kumar R. P21-activated kinases in human cancer. Cancer Metastasis Rev. 2003;22:385-393.
7. McCarty SK, Saji M, Zhang X, et al. Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion. Endocr Relat Cancer. 2010; 17:989-999.
8. Vasko V, Espinosa AV, Scouten W, et al. Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci U S A. 2007;104: 2803-2808.
9. Adam L, Vadlamudi R, Mandal M, Chernoff J, Kumar R. Regulation of microfilament reorganization and invasiveness of breast cancer cells by kinase dead p21-activated kinase-1. J Biol Chem. 2000; 275:12041-12050.
10. Ong CC, Jubb AM, Haverty PM, et al. Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci U S A. 2011;108:7177-7182.
11. Vadlamudi RK, Adam L, Wang RA, et al. Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. J Biol Chem. 2000;275:36238-36244.
12. Holm C, Rayala S, Jirström K, Stål O, Kumar R, Landberg G. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst. 2006;98:671-680.
13. Rayala SK, Molli PR, Kumar R. Nuclear p21-activated kinase 1 in breast cancer packs off tamoxifen sensitivity. Cancer Res. 2006;66: 5985-5988.
14. Hirokawa Y, Nakajima H, Hanemann CO, et al. Signal therapy of NF1-deficient tumor xenograft in mice by the anti-PAK1 drug FK228. Cancer Biol Ther. 2005;4:379-381.
15. Yi C, Wilker EW, Yaffe MB, Stemmer-Rachamimov A, Kissil JL. Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2. Cancer Res. 2008;68:7932-7937.
16. Chow HY, Jubb AM, Koch JN, et al. p21-Activated kinase 1 is required for efficient tumor formation and progression in a Rasmediated skin cancer model. Cancer Res. 2012;72:5966-5975
17. Singhal R, Kandel ES. The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenes. Oncotarget. 2012;3:700-708.
18. Murray BW, Guo C, Piraino J, et al. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Acad Sci U S A. 2010;107: 9446-9451.
19. Deacon SW, Beeser A, Fukui JA, et al. An isoform-selective, smallmolecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem Biol. 2008;15:322-331.
20. Porchia LM, Guerra M, Wang YC, et al. 2-Amino-N-{4-[5-(2-phenanthrenyl)- 3-(trifluoromethyl)-1H-pyrazol-1-yl]-phe nyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase. Mol Pharmacol. 2007;72:1124-1131.
21. Schweppe RE, Klopper JP, Korch C, et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals crosscontamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab. 2008;83:4331-4341.
22. Fabien N, Fusco A, Santoro M, Barbier Y, Dubois PM, Paulin C. Description of a human papillary thyroid carcinoma cell line. Morphologic study and expression of tumoral markers. Cancer. 1994; 73:2206-2212.
23. Tanaka J, Ogura T, Sato H, Hatano M. Establishment and biological characterization of an in vitro human cytomegalovirus latency model. Virology. 1987;161:62-72.
24. Goretzki PE, Frilling A, Simon D, Roeher HD. Growth regulation of normal thyroids and thyroid tumors in man. Recent Results Cancer Res. 1990;118:48-63.
25. Ringel MD, Hayre N, Saito J, et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res. 2001;61:6105-6111.
26. Sells MA, Knaus UG, Bagrodia S, Ambrose DM, Bokoch GM, Chernoff J. Human p21-activated kinase (Pak1) regulates actin organization in mammalian cells. Curr Biol. 1997;7:202-210.
27. Sells MA, Boyd JT, Chernoff J. p21-Activated kinase 1 (Pak1) regulates cell motility in mammalian fibroblasts. J Cell Biol. 1999;145: 837-849.
28. Maksimoska J, Feng L, Harms K, et al. Targeting large kinase active site with rigid, bulky octahedral ruthenium complexes. J Am Chem Soc. 2008;130:15764-15765.
29. Nheu TV, He H, Hirokawa Y, et al. The K252a derivatives, inhibitors for the PAK/MLK kinase family selectively block the growth of RAS transformants. Cancer J. 2002;8:328-336.